Research on prognostic factors in patients with NSCLC receiving CPIs in 2L treatment has mainly focused on one or a few risk factors, such as PD‐L1 expression that has been shown to be prognostic for PD‐L1 agents in NSCLC.8 Here, CD274 is linked to non-small cell lung carcinoma.